Keywords
homocysteine
disease activity
chronic inflammation
clinical forms
xsystemic manifestations
pediatric rheumatology
endothelial dysfunction
biomarkers
How to Cite
Abstract
Juvenile rheumatoid arthritis is a chronic inflammatory disease in which metabolic factors may contribute to disease severity. This study evaluated serum homocysteine levels in 67 children with juvenile rheumatoid arthritis (mean age: 12.4 ± 3.7 years) and analyzed their association with age, disease duration, clinical form, and disease activity. The mean serum homocysteine concentration was 6.6 ± 2.6 μmol/L. Homocysteine levels showed no significant association with age and only a weak correlation with disease duration (r = 0.249; p = 0.043). In contrast, homocysteine concentration differed significantly according to clinical form (p = 0.005) and increased with higher disease activity (p < 0.001). A moderate positive correlation was observed between disease activity and homocysteine level (r = 0.457; p < 0.001). These findings suggest that serum homocysteine reflects inflammatory burden and clinical severity in juvenile rheumatoid arthritis and may have potential value as a disease activity biomarker.
References
Balabanova RM, Kuzmina NN, Erdez SF. Rheumatic diseases in children and adolescents in the Russian Federation (2009–2010). Scientific and Practical Rheumatology. 2013;51(4):446–450.
Khamidova NA, Madjidova YN. Role of homocysteine in the development of juvenile rheumatoid arthritis in children. Bulletin of the Tashkent Pediatric Medical Institute. 2025;6(3):27–33.
Khamidova NA, Madjidova YN. Clinical and neurophysiological features of neurological complications in children with juvenile rheumatoid arthritis: methodological recommendations. Tashkent; 2025. p. 22.
Watutin NT, Smirnova AS, El-Khatib A. Principles of using imaging methods in the diagnosis and treatment of juvenile idiopathic arthritis. Modern Rheumatology Journal. 2015;(4):44–47.
Gaidar EV, Kostik MM, Dubko MF, et al. Efficacy of adalimumab in chronic anterior uveitis associated with juvenile idiopathic arthritis resistant to methotrexate therapy: a retrospective case series. Pediatric Pharmacology. 2016;(4):340–344.
Grom AA. Systemic juvenile idiopathic arthritis: mechanisms of development and targets for biologic therapy. Issues of Modern Pediatrics. 2012;(3).
Kuzmina NN, Vorontsov IM, Nikishina IP, Salugina SO. Evolution of terminology and classification concepts in juvenile chronic arthritis. Scientific and Practical Rheumatology. 2001;(1).
Makunina YU, Yuarov ES, Melnichenko OA. Structure of rheumatic diseases in children based on data from a pediatric hospital clinic over the last 30 years. Bulletin of Medical and Clinical Research. 2014;(4).
This work is licensed under a Creative Commons Attribution 4.0 International License.